saxitoxin and Inflammation

saxitoxin has been researched along with Inflammation* in 3 studies

Trials

1 trial(s) available for saxitoxin and Inflammation

ArticleYear
Evaluation of Neosaxitoxin as a local anesthetic during piglet castration: A potential alternative for Lidocaine.
    Toxicon : official journal of the International Society on Toxinology, 2019, Volume: 164

    To evaluate Neosaxitoxin (NeoSTX) as a local anesthetic drug, for pain control during and after piglet castration.. Prospective, randomized and double-blind study.. 24 commercial hybrids, males, 23-day-old piglets.. The piglets were randomized into two groups: a Lidocaine group and a NeoSTX group. One minute before castration, they were injected intra-scrotally with a single dose of Lidocaine (20 mg, in 1 mL) and NeoSTX (0.1 μg, in 1 mL), respectively.. NeoSTX does not generate vasoconstriction or scrotal contraction, unlike Lidocaine, where a decrease in temperature and scrotal size is observed within 5 min after the procedure. After 24 h, wound inflammation, as measured by scrotal size, was lower in the NeoSTX group. No significant difference could be shown between the vocalizations and facial expressions of pain of both groups during the castration procedure.. A single dose of NeoSTX is safe and effective for pain management during and after piglet castration. NeoSTX treated piglets were less affected by castration than those in the Lidocaine group, thus reducing piglet stress and enhancing the quality of piglet convalescence.

    Topics: Anesthetics, Local; Animals; Inflammation; Lidocaine; Male; Orchiectomy; Pain; Prospective Studies; Random Allocation; Saxitoxin; Scrotum; Skin Temperature; Sus scrofa

2019

Other Studies

2 other study(ies) available for saxitoxin and Inflammation

ArticleYear
Neosaxitoxin, a Paralytic Shellfish Poison phycotoxin, blocks pain and inflammation in equine osteoarthritis.
    Toxicon : official journal of the International Society on Toxinology, 2021, Volume: 204

    The Osteoarthritis is a chronic disease characterized by a progressive deterioration of the articular cartilage producing a strong inflammatory activity and chronic pain in patients. Horses also show osteoarthritis. Since the activation and progression of the disease are similar to that of human we developed a study model in horses. In this study, we test the effect of Neosaxitoxin, a phycotoxin from Paralytic Shellfish Poison, in the remediation of osteoarthritis equine clinical symptoms such as pain (showed in lameness) and inflammation quantifying the amounts of pro-inflammatory markers like cellular infiltration, TNF-alpha and nitric oxide in the synovial fluid obtained from the horse damaged joint. The outcomes show that Neosaxitoxin blocks pain for long lasting period (average 24.7 days). Furthermore, the amounts of pro-inflammatory markers were reduced and consequently an enhanced horse's well-being was obtained. Neosaxitoxin showed to be a candidate for establishing treatment protocols for OA, being safe and effective as a pain blocker in equine osteoarthritis.

    Topics: Animals; Horse Diseases; Horses; Humans; Inflammation; Osteoarthritis; Pain; Poisons; Saxitoxin; Shellfish

2021
Neosaxitoxin Inhibits the Expression of Inflammation Markers of the M1 Phenotype in Macrophages.
    Marine drugs, 2020, May-27, Volume: 18, Issue:6

    (1) Background: Neosaxitoxin (NeoSTX) has been used as a local anesthetic, but its anti-inflammatory effects have not been well defined. In the present study, we investigate the effects of NeoSTX on lipopolysaccharide (LPS)-activated macrophages. (2) Methods: Raw 264.7 and equine PBMC cells were incubated with or without 100 ng/mL LPS in the presence or absence of NeoSTX (1µM). The expression of inflammatory mediators was assessed: nitric oxide (NO) content using the Griess assay, TNF-α content using the ELISA assay, and mRNA of inducible nitric oxide synthase (iNOS), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) using a real-time polymerase chain reaction. (3) Results: NeoSTX (1 μM) significantly inhibited the release of NO, TNF-α, and expression of iNOS, IL-1β, and TNF-α in LPS-activated macrophages of both species studied. Furthermore, our study shows that the LPS-induced release of inflammatory mediators was suppressed by NeoSTX. Additionally, NeoSTX deactivated polarized macrophages to M1 by LPS without compromising its polarization towards M2. (4) Conclusions: NeoSTX inhibits LPS-induced release of inflammatory mediators from macrophages, and these effects may be mediated by the blockade of voltage-gated sodium channels (VGSC).

    Topics: Animals; Humans; Inflammation; Inflammation Mediators; Lipopolysaccharides; Macrophages; Mice; RAW 264.7 Cells; Saxitoxin

2020